Full View

Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction

WT Abraham, MR Zile, FA Weaver, C Butter… - JACC: Heart Failure, 2015 - jacc.org
Objectives: The objective of this clinical trial was to assess the safety and efficacy of carotid
BAT in advanced HF. Background: Increased sympathetic and decreased parasympathetic …
被引用次数：286 相关文章

Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction

W Abraham, M Zile, F Weaver, C Butter… - JACC. HEART …, 2015 - boa.unimib.it
Objectives: The objective of this clinical trial was to assess the safety and efficacy of carotid
BAT in advanced HF. Background: Increased sympathetic and decreased parasympathetic …

[引用][C] Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction

WT Abraham, MR Zile, FA Weaver, C Butter… - JACC: Heart …, 2015 - cir.nii.ac.jp
Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection
Fraction | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …

Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction.

WT Abraham, MR Zile, FA Weaver, C Butter… - JACC. Heart …, 2015 - europepmc.org
Objectives The objective of this clinical trial was to assess the safety and efficacy of carotid
BAT in advanced HF. Background Increased sympathetic and decreased parasympathetic …
[HTML] sciencedirect.com

[HTML][HTML] Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction

WT Abraham, MR Zile, FA Weaver, C Butter… - JACC: Heart Failure, 2015 - Elsevier
Objectives The objective of this clinical trial was to assess the safety and efficacy of carotid
BAT in advanced HF. Background Increased sympathetic and decreased parasympathetic …

Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction

WT Abraham, MR Zile, FA Weaver, C Butter… - 2015 - publications.goettingen-research …
OBJECTIVES The objective of this clinical trial was to assess the safety and efficacy of
carotid BAT in advanced HF. BACKGROUND Increased sympathetic and decreased …

Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction

WT Abraham, MR Zile, FA Weaver, C Butter… - 2015 - pubmed.ncbi.nlm.nih.gov
Objectives The objective of this clinical trial was to assess the safety and efficacy of carotid
BAT in advanced HF. Background Increased sympathetic and decreased parasympathetic …

Baroreflex Activation Therapy for the Treatment of Heart Failure With a ReducedEjection Fraction

WT Abraham, MR Zile, FA Weaver… - JACC: Heart …, 2015 - ohiostate.elsevierpure.com
Objectives: The objective of this clinical trial was to assess the safety and efficacy of carotid
BAT in advanced HF. Background: Increased sympathetic and decreased parasympathetic …

Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction.

WT Abraham, MR Zile, FA Weaver, C Butter… - jichi.ac.jp
目的: 本研究の目的は進行した心不全患者への頸動脈迷走神経刺激療法 (BAT)
の安全性・有効性を評価することである. 背景: 交感神経系の亢進と副交感神経活動の低下が …

[引用][C] Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction

WT Abraham - J. Am. Coll. Cardiol. HF, 2015 - cir.nii.ac.jp
Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction |
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …